TPE	Substitute for form 1449A/PTO		Complete if Known			
CI O 6 20	SIALEMENTR	Y APPLICANT	Application Number	09/699,003		
& TRABE		••	Filing Date	October 26, 2000		
			First Named Inventor	M. Rigdon Lentz		
			Group Art Unit	3762		
			Examiner Name	P. Bianco		
Sheet	1 of	3	Attorney Docket Number	LEN 101 CIP CON		

	U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	US Patent Document Number Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
		(if known)		ĺ						
CAR.		5,980,887	Isner, et al.	11-09-1999						
(X)2		6,017,527	Maraskovsky, et al.	01-25-2000	RECEIVED					
					OCT 1 4 2003					
					TECHNOLOGY CENTER H370					
					-					
		<u> </u>		1						

				F(OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	,	Office.3	Number⁴	Kind Code ⁵ (if known)			r igules Appeal	
202		PCT	WO 91/09967		Celltech Ltd.	07-11-1991		✝
ear		PCT	WO 01/37873		Lentz	05-31-2001		†
				+				\Box
				+		 		╄
=								\vdash

<u></u>				
Examine Signature	Solbranes	Date Considered	2-2-04	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Appr Patent and Tradema	PTC/SB/08A (10-96 oved for use through 10/31/99. OMB 0651-0031 rk Office: U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO				Complete If Known					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/699,003 RECEIVE 0CT 1 4 200						
				Filing Date	October 26, 2000				
				First Named Inventor	M. Rigdon Lentz				
				Group Art Unit	3762				
				Examiner Name	P. Bianco				
Sheet	2	of	3	Attorney Docket Number	LEN 101 CIP CON				

		OTHER ART NON PATENT LITERATURE DOCUMENTS							
Examiner's Initials*	Cite No. ¹								
RMS		ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," Cancer Res. 51: 5602-5607 (1991).							
		AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 resolution," <i>Science</i> 233: 747-751 (1986).							
-		CLACKSON, et al., "Making of antibody fragments using phage display libraries," <i>Nature</i> 352: 624-688 (1991).							
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19: 2471-2476 (1991)							
		DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," <i>J. Clin. Invest</i> 89: 1690-1693 (1992).							
		ELSÄSSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," <i>Tumor Biol.</i> 15: 17-24 (1993).							
		EY, et al., "Isolation of pure IgG ₁ , IgG _{2a} , and IgG _{2b} immunoglobins from mouse serum using protein A- Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).							
		KABAT, et al., eds., <u>Sequences of Proteins of Immunological Interest</u> , 4 th ed., U.S Dept. Health & Human Services: Bethesda, MD (1987).							
		KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," <i>Blood Purif.</i> 11: 150-157 (1993).							
and		LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," <i>Jpn. J. Apheresis</i> 16(1): 107-114 (1997).							

Everninger					
Examiner's Signature	Description	Date Considered	7-	2-04	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please	type a	plus	sign	(+)	inside	this	box →
--------	--------	------	------	-----	--------	------	-------

PTC/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

perwork Reduction	Act of 1995, no	persons are required to respond to	o a collection of information unless it conta	ains a valid OMB control number	
3.7				Complete if Known	RECEIVED
INFOR	MATION	I DISCLOSURE	Application Number	09/699,003	
QTATE	MENT E	BY APPLICANT			OCT 1 4 2003
EFEMALE (use	as many she	eets as necessary)		Т	ECHNOLOGY CENTER R37
			Filing Date	October 26, 2	2000 -
			First Named Inventor	M. Rigdon Le	entz
			Group Art Unit	3762	
			Examiner Name	P. Blanco	
3	of	3	Attorney Docket Number	LEN 101 CIP	CON
•	Substitute for 1003 INFOR STATE	INFORMATION STATEMENT E	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date First Named Inventor Group Art Unit Examiner Name	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date First Named Inventor Group Art Unit Group Art Unit Examiner Name Complete if Known 09/699,003 T Filing Date First Named Inventor Group Art Unit 9762 Examiner Name P. Blanco

	OTHER ART NON PATENT LITERATURE DOCUMENTS						
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
	PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti- digoxin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 85: 3080-3084 (1988).						
	RUDIKOFF, et al., "Single amino acid substitution altering antigen-binding specificity," <i>Immunology</i> 79: 1979-1983 (1982).						
	SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo," Cell. Immunol. 200: 81-87 (2000).						
	SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State University, Fort Collins, Colorado (1999).						
		Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 85: 3080-3084 (1988). RUDIKOFF, et al., "Single amino acid substitution altering antigen-binding specificity," <i>Immunology</i> 79: 1979-1983 (1982). SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence <i>in vivo</i> ," <i>Cell. Immunol.</i> 200: 81-87 (2000). SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State					

Examiners	$O(O_{-1})$	Date Considered	1	
Signature	1 SSURTIONER		2-2-04	
				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.